Anti-CTLA-4 monoclonal antibody (Regeneron) |
REGN-4659 |
Phase 1 Clinical |
Regeneron Pharmaceuticals Inc |
Carcinoma, Non-Small-Cell Lung |
Details
|
B7-2/GM-CSF cancer gene therapy |
CIT |
Phase 1 Clinical |
Radient |
Neoplasms |
Details
|
BA3017 |
BA-3017 |
Phase 1 Clinical |
|
Neoplasms |
Details
|
MGD-019 (MacroGenics) |
MGD-019 |
Phase 1 Clinical |
Macrogenics |
Colorectal Neoplasms |
Details
|
PD-L1/CTLA4 bispecific monoclonal antibody (Changhai Hospital) |
|
Phase 2 Clinical |
Changhai Hospital Of Shanghai |
Pancreatic Neoplasms |
Details
|
Recombinant anti-CTLA-4 human monoclonal antibody (Hualan Biological Engineering) |
|
|
Hualan Genetic Engineering Co Ltd |
Melanoma |
Details
|
ALPN-202 |
ALPN-202 |
Phase 1 Clinical |
Alpine Immune Sciences |
Lymphoma |
Details
|
XmAb-22841 |
XmAb-22841 |
Phase 1 Clinical |
Xencor |
Prostatic Neoplasms; Carcinoma, Hepatocellular; Adenocarcinoma; Melanoma; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung; Fallopian Tube Neoplasms; Peritoneal Neoplasms; Microsatellite Instability; Squamous Cell Carcinoma of Head and Neck; Nasopharyngeal Carcinoma; Cholangiocarcinoma; Small Cell Lung Carcinoma; Triple Negative Breast Neoplasms; Carcinoma, Transitional Cell; Carcinoma, Ovarian Epithelial; Carcinoma, Renal Cell |
Details
|
Anti-CTLA-4 and PD-1 CAR-T cell therapy (Shanghai Cell Therapy Research Institute) |
|
Phase 2 Clinical |
Shanghai Cell Therapy Research Institute |
Neoplasms |
Details
|
MEDI-5752 |
MEDI-5752 |
Phase 1 Clinical |
Medimmune Llc |
Carcinoma, Renal Cell; Neoplasms |
Details
|
BCD-217 |
BCD-217 |
Phase 2 Clinical |
Biocad |
Melanoma |
Details
|
Recombinant anti-CTLA-4 human monoclonal antibody (Henlius) |
|
Phase 1 Clinical |
Shanghai Henlius Biotech Co Ltd |
Carcinoma, Renal Cell; Colorectal Neoplasms; Melanoma |
Details
|
Recombinant human anti-CTLA-4 monoclonal antibody (Mab-Venture/ShuangLu Pharmaceutical) |
|
Phase 1 Clinical |
Shanghai Mab-Venture Biopharm Co Ltd, Beijing Sl Pharmaceutical Co Ltd |
Neoplasms |
Details
|
IO-102 |
IO-102 |
Phase 2 Clinical |
Herlev Hospital, Merck Sharp & Dohme Corp, Io Biotech |
Carcinoma, Non-Small-Cell Lung; Melanoma |
Details
|
FPT-155 |
CD80-Fc; FPT-155 |
Phase 1 Clinical |
Five Prime Therapeutics |
Neoplasms |
Details
|
XmAb20717 |
XmAb-20717 |
Phase 1 Clinical |
Xencor |
Astrocytoma; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Adenocarcinoma; Melanoma; Endometrial Neoplasms; Fallopian Tube Neoplasms; Carcinoma, Squamous Cell; Carcinoma, Neuroendocrine; Thymoma; Colorectal Neoplasms; Carcinoma, Renal Cell; Prostatic Neoplasms; Vulvar Neoplasms; Breast Neoplasms; Nasopharyngeal Carcinoma; Cholangiocarcinoma; Mesothelioma; Carcinoma, Ovarian Epithelial; Small Cell Lung Carcinoma; Carcinoma, Transitional Cell; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Basal Cell |
Details
|
ATOR-1015 |
ADC-1015; ATOR-1015 |
Phase 1 Clinical |
Alligator Bioscience |
Neoplasms |
Details
|
Abatacept (Orban Biotech) |
|
Phase 2 Clinical |
Orban Biotech, The National Institute Of Diabetes And Digestive And Kidney Diseases |
Diabetes Mellitus, Type 1 |
Details
|
RP-2 |
RP-2 |
Phase 1 Clinical |
Replimune, Bristol-Myers Squibb Company |
Neoplasms |
Details
|
BMS-986249 |
BMS-986249 |
Phase 2 Clinical |
Cytomx Therapeutics |
Neoplasms |
Details
|
Anti-CTLA-4 antibody (Agenus) |
AGEN-1181 |
Phase 2 Clinical |
Agenus Inc |
Neoplasms |
Details
|
ADG-116 |
ADG-116; ADG116 |
Phase 1 Clinical |
Adagene (Suzhou) Ltd |
Solid tumours |
Details
|
BT-001 |
BT-001 |
Phase 2 Clinical |
Transgene |
Solid tumours; Carcinoma, Merkel Cell; Triple Negative Breast Neoplasms; Neoplasms; Sarcoma; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis; Melanoma |
Details
|
Zalifrelimab |
AGEN-1884; RebmAb-600 |
Phase 2 Clinical |
4-Antibody, Ludwig Institute For Cancer Research |
Solid tumours; Hemangiosarcoma; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms |
Details
|
YH-001 |
YH-001 |
Phase 2 Clinical |
Eucure Pharmaceutical Technology (Beijing) Co Ltd |
Solid tumours; Melanoma |
Details
|
Ipilimumab biosimilar (Innovent Biologics) |
IBI-310 |
Phase 3 Clinical |
Innovent Biologics(Suzhou) Co Ltd |
Solid tumours; Liver Neoplasms; Colorectal Neoplasms; Carcinoma, Hepatocellular; Uterine Cervical Neoplasms; Melanoma |
Details
|
ONCR-177 |
ONCR-177 |
Phase 1 Clinical |
Oncorus |
Solid tumours; Liver Neoplasms; Squamous Cell Carcinoma of Head and Neck; Triple Negative Breast Neoplasms; Skin Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Melanoma |
Details
|
IDO-derived peptide vaccine/PD-L1-derived peptide vaccine |
IO-102/IO-103 |
Phase 2 Clinical |
Herlev Hospital |
Melanoma |
Details
|
ONC-392 |
ONC-392 |
Phase 1 Clinical |
Oncoimmune |
Solid tumours; Ovarian Neoplasms; Head and Neck Neoplasms; Carcinoma, Renal Cell; Small Cell Lung Carcinoma; Sarcoma; Prostatic Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Melanoma; Carcinoma, Non-Small-Cell Lung |
Details
|
AK-104 |
AK-104 |
Phase 2 Clinical |
Zhongshan Akeso Biopharma Co Ltd |
Lymphoma, T-Cell, Peripheral; Solid tumours; Stomach Neoplasms; Esophageal Neoplasms; Nasopharyngeal Carcinoma; Microsatellite Instability; Uterine Cervical Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Adenocarcinoma; Melanoma |
Details
|
MK-1308 |
MK-1308 |
Phase 2 Clinical |
Merck Sharp & Dohme Corp |
Solid tumours; Carcinoma, Renal Cell; Melanoma; Carcinoma, Non-Small-Cell Lung |
Details
|
HBM-4003 |
HBM-4003 |
Phase 1 Clinical |
Harbour Biomed |
Solid tumours; Melanoma |
Details
|
ADG-126 |
|
Phase 1 Clinical |
Adagene Inc |
Neoplasm Metastasis |
Details
|
Tremelimumab |
CP-675; CP-675206 |
Phase 3 Clinical |
Pfizer Inc |
Pancreatic Neoplasms; Melanoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Lymphoma, Non-Hodgkin; Urogenital Neoplasms; Esophageal Squamous Cell Carcinoma; Carcinoma, Pancreatic Ductal; Fallopian Tube Neoplasms; Lung Neoplasms; Colorectal Neoplasms; Peritoneal Neoplasms; Breast Neoplasms; Prostatic Neoplasms; Mesothelioma; Digestive System Neoplasms; Hematologic Neoplasms; Lymphoma, Large B-Cell, Diffuse; Triple Negative Breast Neoplasms; Carcinoma, Transitional Cell; Small Cell Lung Carcinoma; Stomach Neoplasms; Esophageal Neoplasms; Carcinoma, Renal Cell; Carcinoma; Squamous Cell Carcinoma of Head and Neck; Solid tumours; Head and Neck Neoplasms; Liver Neoplasms; Ovarian Neoplasms; Biliary Tract Neoplasms |
Details
|
KN-046 |
KN046; KN-046 |
Phase 3 Clinical |
Suzhou Alphamab Co Ltd |
Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Triple Negative Breast Neoplasms; Breast Neoplasms; Thymus Neoplasms; Lymphoma; Esophageal Squamous Cell Carcinoma; Thymoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Gastrointestinal Neoplasms |
Details
|
CS-1002 |
CS-1002 |
Phase 1 Clinical |
Cstone Pharmaceuticals |
Solid tumours |
Details
|
KN-044 |
KN-044 |
Phase 1 Clinical |
Suzhou Alphamab Co Ltd |
Solid tumours |
Details
|